CXCR4
CXCL12
CXCR4
Interstitial lung disease
Pulmonary fibrosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Aug 2020
26 Aug 2020
Historique:
received:
11
03
2020
accepted:
23
07
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
20
7
2021
Statut:
epublish
Résumé
CXCR4, a transmembrane-receptor located on epithelial cells that is activated by CXCL12, may have a role in IPF via migration of CXCR4 Expression of CXCR4 on peripheral blood mononuclear cells (PBMCs) was examined by flow cytometry in 20 patients with IPF and 10 age-matched non-disease control (NDC) donors. Levels of CXCL12 in human plasma were measured by ELISA. Expression of CXCR4, CXCL12, CD45, and e-cadherin was assessed in IPF (n = 10), other fibrotic ILD (n = 8) and NDC (n = 10) lung tissue by multiplex immunohistochemistry (OPAL) and slides were scanned using a Vectra 3 scanner. Cells were quantified with computer automated histological analysis software (HALO). In blood, the number of CXCR4 This report demonstrates that CXCR4 is overexpressed not only in IPF but also in other ILDs and expression is particularly prominent within both honeycomb cysts and distal airway epithelium. This observation supports the hypothesis that CXCR4 may drive tissue fibrosis through binding its specific ligand CXCL12. Although CXCR4 expressing cells could be either of epithelial or myeloid origin it appears that the former is more prominent in IPF lung tissue. Further characterization of the cells of the honeycomb cyst may lead to a better understanding of the fibrogenic processes in IPF and other end-stage fibrotic ILDs.
Sections du résumé
BACKGROUND
BACKGROUND
CXCR4, a transmembrane-receptor located on epithelial cells that is activated by CXCL12, may have a role in IPF via migration of CXCR4
METHODS
METHODS
Expression of CXCR4 on peripheral blood mononuclear cells (PBMCs) was examined by flow cytometry in 20 patients with IPF and 10 age-matched non-disease control (NDC) donors. Levels of CXCL12 in human plasma were measured by ELISA. Expression of CXCR4, CXCL12, CD45, and e-cadherin was assessed in IPF (n = 10), other fibrotic ILD (n = 8) and NDC (n = 10) lung tissue by multiplex immunohistochemistry (OPAL) and slides were scanned using a Vectra 3 scanner. Cells were quantified with computer automated histological analysis software (HALO).
RESULTS
RESULTS
In blood, the number of CXCR4
CONCLUSIONS
CONCLUSIONS
This report demonstrates that CXCR4 is overexpressed not only in IPF but also in other ILDs and expression is particularly prominent within both honeycomb cysts and distal airway epithelium. This observation supports the hypothesis that CXCR4 may drive tissue fibrosis through binding its specific ligand CXCL12. Although CXCR4 expressing cells could be either of epithelial or myeloid origin it appears that the former is more prominent in IPF lung tissue. Further characterization of the cells of the honeycomb cyst may lead to a better understanding of the fibrogenic processes in IPF and other end-stage fibrotic ILDs.
Identifiants
pubmed: 32843095
doi: 10.1186/s12931-020-01467-0
pii: 10.1186/s12931-020-01467-0
pmc: PMC7449054
doi:
Substances chimiques
Biomarkers
0
CXCR4 protein, human
0
Receptors, CXCR4
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
221Subventions
Organisme : Department of Industry, Innovation and Science, Australian Government
ID : RC50408 and RC55633
Références
Immunology. 1999 Sep;98(1):36-41
pubmed: 10469231
Int J Biochem Cell Biol. 2008;40(10):2129-40
pubmed: 18374622
Am J Respir Crit Care Med. 2016 Apr 1;193(7):792-800
pubmed: 27035782
Cytometry B Clin Cytom. 2014 Sep;86(5):340-9
pubmed: 24500843
BMC Cancer. 2019 Feb 13;19(1):148
pubmed: 30760238
Sci Rep. 2017 May 19;7(1):2155
pubmed: 28526890
Connect Tissue Res. 2010;51(1):71-80
pubmed: 20067420
Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L846-56
pubmed: 22345572
Am J Respir Crit Care Med. 2015 Feb 15;191(4):427-36
pubmed: 25531246
Curr Health Sci J. 2019 Jan-Mar;45(1):73-78
pubmed: 31297266
Sci Rep. 2018 Feb 16;8(1):3212
pubmed: 29453386
J Clin Invest. 2004 Aug;114(3):438-46
pubmed: 15286810
Am J Respir Cell Mol Biol. 2007 Sep;37(3):291-9
pubmed: 17463394
Respirology. 2017 Oct;22(7):1436-1458
pubmed: 28845557
Biomed Res Int. 2015;2015:329481
pubmed: 26779535
PLoS One. 2013 Oct 14;8(10):e77160
pubmed: 24155926
Biochem Biophys Res Commun. 2007 Feb 2;353(1):104-8
pubmed: 17174272
Annu Rev Pathol. 2014;9:157-79
pubmed: 24050627
Immunol Lett. 2012 Jul 30;145(1-2):47-54
pubmed: 22698183
J Pathol. 2003 Nov;201(3):343-54
pubmed: 14595745
J Leukoc Biol. 2007 Sep;82(3):449-56
pubmed: 17550974
Am J Respir Crit Care Med. 2019 Jul 15;200(2):220-234
pubmed: 30973754
Respirology. 2017 Oct;22(7):1459-1472
pubmed: 28891101
Thorax. 2003 Feb;58(2):143-8
pubmed: 12554898
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):449-61
pubmed: 20646340
Am J Respir Crit Care Med. 2009 Apr 1;179(7):588-94
pubmed: 19151190
Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1708-18
pubmed: 19433312
PLoS One. 2013;8(3):e58658
pubmed: 23527003
Am J Pathol. 2017 Aug;187(8):1772-1786
pubmed: 28618253
Eur Respir Rev. 2018 Dec 21;27(150):
pubmed: 30578336
J Thorac Cardiovasc Surg. 2009 Mar;137(3):615-21
pubmed: 19258077